This information is for research and educational purposes only. No medical recommendations. Products are not approved for human use. For health questions, consult a doctor.

Lexicon

Hyaluronic Acid - Injection Preparation

Naturally occurring polysaccharide for intra-articular and aesthetic injections in research contexts.

2 min read 9 sources

Vial with white powder and the black TPD label for hyaluronic acid on a white podium, next to it a molecule of blue and white spheres with two rings in a bright lab
Compound approved · for specific uses

Summary

At a glance

Sources checked on 26 Oct 2026

In the largest knee review
89 trials

12,667 adults with knee osteoarthritis, joint injection versus sham or no treatment2

Pain in large blinded trials
-0.11 SMD

clinically irrelevant according to the authors, across all trials -0.372

More serious adverse events
+41 %

relative risk 1.41 in 14 trials with 3,667 people2

Half-life in the knee joint
13.2 hours

high molecular weight hyaluronic acid in rabbits, low molecular weight 10.2 hours4

Hyaluronic acid in vision loss after fillers
79.6 %

share of 365 newly reported cases from 2018 to 2023 after facial filler injection7

  • Hyaluronic acid is a long-chain sugar (polysaccharide) that occurs naturally in connective tissue, joint fluid and skin. It binds water and makes fluids viscous and slippery.5
  • The body turns it over quickly: in tissue its half-life ranges from less than one to several days, in the knee joint of rabbits it was 10 to 13 hours. Cells bind it via the receptor CD44.546
  • As an injection into the knee joint for osteoarthritis it is well studied. The largest review of 89 trials found only a small, clinically irrelevant effect on pain and more serious adverse events.2
  • An older Cochrane review rated the trials more positively. According to both reviews, the size of the effect depends strongly on product, time point and trial quality.32
  • As a facial filler, hyaluronic acid can block a blood vessel, up to blindness. Everything here is the state of research, not a recommendation.7
Profile

Updated June 2026

Class
Natural polysaccharide
Use
Joints

skin; research purposes

Half-life
Short: from under one to several days in tissue, a few minutes in the blood
Status
Regulated

not on the WADA Prohibited List

Sizes
5 mg

1 size in the shop

Contents 13 sections
  1. At a glance
  2. What is Hyaluronic Acid?
  3. How it works
  4. Use
  5. What the research shows
  6. Research status
  7. On the skin
  8. Side effects
  9. Storage
  10. Related compounds
  11. FAQ
  12. Glossary
  13. Sources

What is Hyaluronic Acid?

Hyaluronic acid (HA) is a naturally occurring linear polysaccharide composed of repeating units of glucuronic acid and N-acetylglucosamine. It is a structural component of connective tissue, synovial fluid and skin. Injectable HA preparations are investigated in research contexts for joint and skin hydration.

This information is for research and educational purposes only. No medical advice.

Comparison

Further entries on skin and joints

Where each compound acts, as stated in the TPD lexicon. Tap a card to open its entry.

Sugar polymer, binds water Hyaluronic Acid - Injection Preparation CD44
Copper peptide, focus on skin GHK-Cu Peptide, focus on tendons and tissue BPC-157

Simplified: hyaluronic acid is a sugar polymer, not a peptide. The other entries are peptides with a different approach.

How it works

Hyaluronic acid acts as a viscoelastic substance and moisture reservoir. It binds large amounts of water (up to 1000 times its molecular weight) and creates cushioning and lubrication in joints and hydration in skin.

  • Highly hygroscopic (binds water)
  • Viscoelastic polymer
  • Anti-inflammatory properties
  • Natural component of joints and skin

Where it acts

Where hyaluronic acid plays a role

Tap a point or a card. Colour = receptor, grey = effect seen in trials.

  1. Knee joint

    As an injection in osteoarthritis, a small, clinically irrelevant effect on pain in large trials2

    Observed in trials
  2. Skin and connective tissue

    Natural component, cells bind hyaluronic acid via CD446

    CD44
  3. Eye

    Vision loss when facial filler blocks a blood vessel, mostly without recovery7

    Observed in trials
  4. Liver

    Breaks down hyaluronic acid from the blood, half-life in the blood 2 to 5 minutes5

    Observed in trials

Known targets6

Compound CHEMBL5314376: one described target, Main receptor on the cell surface, binds hyaluronic acid.

CD44 (hyaluronic acid receptor)
Gene
CD44
UniProt
P16070
ChEMBL
CHEMBL3232692
Action
Main receptor on the cell surface, binds hyaluronic acid
Glass knee joint with a bluish network with bubbles in the joint space, molecules of blue and white spheres on the left and right
Hyaluronic acid makes joint fluid viscous and slippery. Symbolic image.

Use

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts

What the research shows

Hyaluronic acid is well established in medical research. In knee osteoarthritis the trials show less pain overall. A review of 89 trials, however, concluded that the benefit is small and of little clinical relevance, with the smallest effect in large blinded trials (Rutjes 2012). In skin research, HA is examined as a moisturizer and potential collagen stimulator. Safety data are thin: many joint trials did not report safety data.

  • Small effect of little clinical relevance on pain in knee osteoarthritis (Rutjes 2012)
  • Skin hydration studies show positive effects
  • Biocompatible, but more serious adverse events than placebo in joint trials
  • Naturally occurring, low immunogenicity

Study results

What the trials measured

Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.

Effect on pain2

Effect size versus sham or no treatment, by type of trial

All trials2 71 trials, 9,617 people
Hyaluronic acid, difference from control -0.37 SMD
Large blinded trials2 18 trials, 5,094 people
Hyaluronic acid, difference from control -0.11 SMD
Unpublished trials2 5 trials, 1,149 people
Hyaluronic acid, difference from control -0.03 SMD

The larger and better blinded the trials, the smaller the effect. The authors rate it as clinically irrelevant. As a rule of thumb an effect size around 0.2 counts as small and around 0.5 as moderate.

Risk compared with control2

Relative risk, 1 means as frequent as without hyaluronic acid

Serious adverse events2 14 trials, 3,667 people, significant
Hyaluronic acid, risk relative to control 1.41-fold
Flare-ups in the joint2 6 trials, 811 people, not significant
Hyaluronic acid, risk relative to control 1.51-fold

Values from the abstract of the review. Many trials did not report safety data at all and trial quality was generally low. The older Cochrane review found few adverse events in the trials, but numbers too small for a firm judgement.

Half-life in the knee joint4

Labelled hyaluronic acid injected into rabbit knees, in hours

High molecular weight4 4 rabbits
Hyaluronic acid in the knee joint 13.2 h
Low molecular weight4 4 rabbits
Hyaluronic acid in the knee joint 10.2 h

Long chains stayed only slightly longer in the joint than short ones. In the blood the half-life is 2 to 5 minutes, where hyaluronic acid is mainly broken down in the liver.

Model of skin layers on a glass plate, surrounded by Petri dishes with clear gel, water droplets and a glass rod
Studies on joints and skin. Symbolic image.

Research status

Where the research stands

ClinicalTrials.gov lists 288 entries on hyaluronic acid as a joint injection for knee osteoarthritis. Shown is a selection of large, completed phase 3 trials against placebo. As of 26 Oct 2026. 8

  1. Preclinical Breakdown in the knee joint (rabbits)
  2. Phase 1 no registered trial
  3. Phase 2 no registered trial
  4. Phase 3 5 trials, 5 completed
  5. Approval for specific uses
2,528 participants in phase 3 ChEMBL lists hyaluronic acid with highest phase 4, i.e. as approved. It is used among other things as a joint injection for knee osteoarthritis and as a facial filler.9
Show all 5 phase 3 trials on a timelineHide timeline 5 completed 0 running 0 with results
Phase 3

Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026.

On the skin

Besides injection, hyaluronic acid is a common ingredient in creams and serums applied to the skin. A review sums up that such products improved skin hydration in studies and were well tolerated (Bravo 2022). The review comes from a cosmetics company's side.

Hand touching a swirl of white cream on a light marble slab with water droplets and white flowers
Symbolic image.

Side effects

Hyaluronic acid occurs naturally in the body, yet the injection is not free of risk:

  • Local injection reactions (temporary, mild)
  • Occasional local inflammation or swelling
  • Allergic reactions are rare
  • In joint trials serious adverse events were more frequent than with placebo (relative risk 1.41, Rutjes 2012)
  • The biggest danger is injection into a blood vessel: hyaluronic acid can block it, with facial fillers up to blindness, mostly without recovery (Doyon 2024)

Storage

Hyaluronic acid vials should be stored cool and dark. The exact storage conditions depend on the formulation - typically refrigeration (2-8°C) is recommended. After opening, it should be used promptly, but unopened vials are stable for extended periods.

  • Store cool (2-8°C recommended)
  • Protected from light
  • Do not freeze
  • Keep original packaging dry
Nine vials with white powder and blue caps in the door shelf of a bright fridge
Store cool (2 to 8 degrees) and protected from light, do not freeze. Symbolic image.

Related

Related compounds

A different path: all in the TPD lexicon.

FAQ

Common questions about Hyaluronic Acid - Injection Preparation

Short answers, each backed by the sources below.

What is hyaluronic acid?

A very long-chain sugar (polysaccharide) found in all tissues and body fluids, especially in loose connective tissue. It makes fluids viscous, acts as a lubricant and holds water in tissue.5

How long does hyaluronic acid stay in the body?

Not long. In tissue the half-life ranges from less than one to several days. Injected into the knee joint of rabbits it was 13.2 hours for long and 10.2 hours for short chains. Whatever reaches the blood is mainly broken down by the liver within minutes.54

Does the knee injection help in osteoarthritis?

The effect is small. The largest review of 89 trials found moderate pain relief across all trials, but only a clinically irrelevant effect in large blinded trials. An older Cochrane review saw a 28 to 54 percent improvement in pain from baseline 5 to 13 weeks after the injection.23

Why do the reviews contradict each other?

Because the size and quality of trials strongly affect the result. Small trials and trials without blinded assessment showed larger effects, unpublished trials almost none. The Cochrane review also found large differences by product, time point and outcome.23

What are the risks of the knee injection?

In 14 trials with 3,667 people serious adverse events were more frequent with hyaluronic acid, the relative risk was 1.41. Flare-ups in the joint were also more common, but the difference was not significant. Many trials did not report safety data.2

What are the risks as a facial filler?

If filler gets into a blood vessel it can block it. A review found 365 new cases of vision loss after fillers between 2018 and 2023, 79.6 percent of them with hyaluronic acid. The nose, forehead and frown area were most often involved. 68.2 percent of those affected did not regain their vision.7

Is hyaluronic acid approved?

Yes, ChEMBL lists it with highest phase 4. ClinicalTrials.gov alone lists 288 entries on knee osteoarthritis. It is approved for specific uses, each time as a specific product.98

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

CD44
Protein on the cell surface through which cells bind hyaluronic acid.
Cochrane review
Systematic review following the strict rules of the Cochrane organisation.
Effect size (SMD)
Standardised difference between two groups. Around 0.2 counts as small, around 0.5 as moderate, around 0.8 as large.
Filler
Gel injected under the skin to smooth wrinkles or add volume. Usually based on hyaluronic acid.
Half-life
Time after which only half of a substance is left.
Intra-articular
Injected into a joint.
Knee osteoarthritis
Wear of the cartilage in the knee joint with pain and limited movement.
Molecular weight
Mass of a molecule. For hyaluronic acid a measure of how long the chains are.
Polysaccharide
Long-chain sugar of many identical building blocks. In hyaluronic acid these are glucuronic acid and N-acetylglucosamine in turn.
Relative risk
How much more often an event occurs in one group than in the other. 1.41 means 41 percent more often.
Synovial fluid
Viscous fluid in the joint that lubricates the cartilage surfaces. Hyaluronic acid makes it viscous.
Viscosupplementation
Technical term for injecting hyaluronic acid into a joint to supplement the joint fluid.

Evidence

Sources

Show all 9 sourcesHide sources 7 Studies1 Trial registry1 Database checked 26 Oct 2026

Studies

  1. Review of hyaluronic acid in creams and serums

    Bravo et al., Dermatologic Therapy, 2022

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  2. Review of 89 trials: hyaluronic acid in knee osteoarthritis

    Rutjes et al., Annals of Internal Medicine, 2012

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  3. Cochrane review: hyaluronic acid in knee osteoarthritis

    Bellamy et al., Cochrane Database of Systematic Reviews, 2006

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  4. Breakdown of hyaluronic acid in the knee joint (rabbits)

    Brown et al., Experimental Physiology, 1991

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  5. Review: structure, occurrence, functions and turnover

    Fraser et al., Journal of Internal Medicine, 1997

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  6. CD44 as the main receptor for hyaluronic acid

    Aruffo et al., Cell, 1990

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  7. Review: vision loss after fillers

    Doyon et al., Aesthetic Surgery Journal, 2024

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed

Trial registry

  1. Trials of hyaluronic acid in knee osteoarthritis in the registry

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. Hyaluronic acid in ChEMBL (approval status)

    ChEMBL, EMBL-EBI (CHEMBL5314376)

    Checked 26 Oct 2026 via ChEMBL

In the shop

Hyaluronic Acid - Injection Preparation in the catalog

Sizes, prices and shipping times are on the product page.

To the product